This clinical trial is focused on patients experiencing an acute abdomen, which refers to sudden and severe abdominal pain that may require urgent medical attention. The study is particularly interested in patients who also have impaired renal function, meaning their kidneys are not working as well as they should. The trial will compare two types of computed tomography (CT) scans: one using an intravenous (IV) contrast called Omnipaque, which contains the active substance iohexol, and the other without any contrast.

The purpose of the study is to determine if using the IV contrast CT is better at diagnosing the cause of acute abdomen in these patients compared to a CT scan without contrast. Participants will be randomly assigned to receive either the contrast-enhanced CT or the non-contrast CT. The study will monitor participants for up to 90 days to observe outcomes such as overall survival, the need for kidney support treatments, and any changes in kidney function.

Throughout the study, researchers will also look at other factors, such as the severity of any acute kidney injury (AKI)</b) that might occur, any organ dysfunction, and the number of days participants spend out of the hospital. The study aims to provide valuable information on the best imaging approach for patients with acute abdomen and impaired kidney function, potentially improving diagnosis and treatment strategies in the future.